When did Jazz Pharmaceuticals report Q2 2025 earnings?

Jazz Pharmaceuticals (JAZZ) reported Q2 2025 earnings on August 5, 2025 after market close.

What were Jazz Pharmaceuticals's Q2 2025 revenue and EPS?

Jazz Pharmaceuticals reported revenue of $1.0B and eps of $-8.25 for Q2 2025.

Did Jazz Pharmaceuticals beat estimates in Q2 2025?

Revenue missed the consensus estimate of $1.0B by $1.5M. EPS missed the consensus estimate of $-6.12 by $2.13.

How did Jazz Pharmaceuticals's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 2.1% from $1.0B a year earlier.

Where can I find Jazz Pharmaceuticals's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0001232524-25-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.

Jazz Pharmaceuticals JAZZ Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$1.0BMiss by $1.5M

EPS-$8.25Miss by $2.13

Revenue estimate$1.0B

EPS estimate-$6.12

Next report

Aug 3, 2026 (In 4 days)

Revenue estimate$1.1B

EPS estimate$6.18

Financials

Q2 2025

Income statement

See full

Revenue$1.0B+2.1%

Operating income-$686.4M-444%

Net income-$718.5M-526%

EPS (diluted)-$11.74-571%

Balance sheet

See full

Cash & equivalents$1.2B-12.2%

Total debt$5.4B-6.2%

Total equity$3.7B-1.5%

Total assets$10.9B-3.7%

Cash flow

See full

Operating cash flow$88.8M-73.2%

CapEx$12.9M+82.6%

Free cash flow$75.9M-76.6%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$6.54B-2.0%

Enterprise value$10.77B-2.9%

P/S1.6×-0.1×

Profitability

See full

Operating margin-7.1%-21.5pp

Net margin-9.9%-20.0pp

FCF margin31%+4.2pp

Returns & leverage

See full

Return on equity-10.8%-21.7pp

Debt / equity1.5×-0.1×

Current ratio1.6×-0.7×

Segments

By product

See full

Xywav$415.3M+12.7%

Epidiolex/Epidyolex$251.7M+1.9%

Rylaze/Enrylaze$100.7M-6.6%

Zepzelca$74.5M-8.0%

High-sodium oxybate AG royalty revenue$54.1M0.0%

By geography

See full

Europe$82.8M+0.7%

All other$26.7M+56.2%

Versus estimates

Revenue

Q1 2026$1.1BBeat by $90.2M Q4 2025$1.2BBeat by $32.7M Q3 2025$1.1BBeat by $15.0M

Q2 2025$1.0BMiss by $1.5M

Q1 2025$897.8MMiss by $167.0M Q4 2024$1.1BBeat by $103.2M

Diluted EPS

Q1 2026$6.34Beat by $1.67 Q4 2025$6.64Beat by $0.12 Q3 2025$8.13Beat by $2.18

Q2 2025-$8.25Miss by $2.13

Q1 2025$1.68Miss by $2.83 Q4 2024$6.60Beat by $0.77

Ask the moment Jazz Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Jazz Pharmaceuticals report Q2 2025 earnings?: Jazz Pharmaceuticals (JAZZ) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Jazz Pharmaceuticals's Q2 2025 revenue and EPS?: Jazz Pharmaceuticals reported revenue of $1.0B and eps of $-8.25 for Q2 2025.
Did Jazz Pharmaceuticals beat estimates in Q2 2025?: Revenue missed the consensus estimate of $1.0B by $1.5M. EPS missed the consensus estimate of $-6.12 by $2.13.
How did Jazz Pharmaceuticals's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 2.1% from $1.0B a year earlier.
Where can I find Jazz Pharmaceuticals's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001232524-25-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.